(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credits: Canva
A widely used medication prescribed to lower cholesterol and reduce the risk of heart disease may trigger uncomfortable side effects in some people, including nosebleeds. In England, around 5.3 million people are currently taking statins, a group of drugs designed to help bring cholesterol levels down.
Atorvastatin, sold under brand names such as Lipitor, is a commonly prescribed statin medication. Doctors use it to lower cholesterol levels and help reduce the risk of heart attacks, strokes, and other cardiovascular problems, as per Mayo Clinic.
Atorvastatin is commonly prescribed to people with raised cholesterol, as well as those who have a family history of heart disease or long-term conditions such as diabetes or arthritis. NHS guidance explains that the medicine is usually taken as a tablet, with chewable options available for people who struggle to swallow pills.
High cholesterol can cause fatty deposits to build up in blood vessels, increasing the risk of serious complications such as heart attacks and strokes. It is also a major factor in cardiovascular disease, which is responsible for more than a quarter of all deaths in England.
While atorvastatin is effective at lowering the risk of cardiovascular disease, it is not suitable for everyone. Like many medicines, it can cause side effects in some people, particularly when taken over long periods. Others may take it for years without noticing any problems at all.
The NHS advises that atorvastatin is generally not recommended during pregnancy, as it may pose risks to a developing baby. If someone becomes pregnant while taking the drug, they are advised to stop using it and speak to a doctor as soon as possible.
Alternative treatments may be offered during pregnancy. Women may also be advised to stop taking atorvastatin while breastfeeding. It is not yet clear how much of the drug passes into breast milk or whether it could cause side effects in infants.
NHS guidance stresses the importance of seeking medical advice if you are taking atorvastatin and are trying to conceive, are already pregnant, or are breastfeeding. You should also speak to a doctor before taking atorvastatin if you:
Disclaimer:
This information is for general awareness only and is not a substitute for medical advice. Always consult a qualified doctor or healthcare professional before starting, stopping, or changing any medication.
Credits: Canva
More than 2,000 measles cases have been recorded in the United States this year, according to federal health data, marking the highest annual total the country has seen in several decades.
Active outbreaks, most notably in upstate South Carolina and in communities along the Arizona-Utah border — are continuing to report new infections each week. Health officials warn that this sustained spread could jeopardise the measles elimination status the US has maintained for the past 25 years.
As of December 30, a total of 2,065 confirmed measles cases had been reported nationwide in 2026, based on figures released Wednesday by the US Centers for Disease Control and Prevention. The last time annual measles infections crossed the 2,000 mark was in 1992, shortly after public health authorities revised vaccination guidance to recommend two doses of the measles-mumps-rubella (MMR) vaccine for children instead of one.
Measles is among the most infectious diseases known, but it can be prevented through vaccination. The CDC says a single dose of the MMR vaccine is about 93 percent effective at preventing measles, while two doses increase protection to 97 percent. Despite this, immunisation coverage has been slipping steadily over recent years.
CDC data shows that during the last school year, only 92.5 percent of children entering kindergarten had received the MMR vaccine. This falls below the 95 percent coverage level that public health experts say is needed to prevent outbreaks and protect communities through herd immunity.
The US has been considered measles-free since 2000, a designation that means no continuous chains of transmission have lasted longer than a year. However, several large outbreaks reported this year may be linked, raising concerns that ongoing transmission could persist beyond late January and threaten that status.
One major outbreak that began in West Texas in late January was officially declared over in mid-August. That outbreak led to hundreds of related cases across Texas and New Mexico and resulted in three deaths — two children and one adult — all of whom were unvaccinated.
In early October, South Carolina’s health department confirmed a measles outbreak in the state’s upstate region. Over the past four months, that outbreak has grown to nearly 180 cases and continues to spread. At least 20 new infections have been reported since Friday, and close to 300 people are currently in quarantine due to exposure to confirmed cases.
“We know that many of the cases we are seeing involve people who were already under quarantine because of known exposure,” said Dr Linda Bell, South Carolina’s state epidemiologist, speaking on Tuesday. She added that the virus is spreading within households as well as in schools and churches.
Another significant outbreak remains active along the Utah-Arizona border, where more than 350 measles cases have been reported between the two states so far this year.
In November, the Pan American Health Organization, which operates under the World Health Organization, announced that Canada had lost its measles elimination status due to a large and ongoing outbreak.
“At the same time, the remaining 34 countries in the region continue to hold their measles-free certification,” said PAHO Director Dr Jarbas Barbosa.
Health officials say potential genetic connections between the Texas outbreak earlier this year and the ongoing outbreak in South Carolina could pose a serious challenge to the US designation.
“The trend we are seeing suggests that more cases are likely to occur well into January,” Bell said. “What that means for our national status as a country that has eliminated measles is still uncertain.”
Credits: Canva
A dangerous superbug that does not respond to most antibiotics is spreading rapidly across the United States, with Alabama reporting 158 cases so far this year. The data, shared by the Alabama Department of Public Health, highlights growing concern among health officials as infections continue to rise in healthcare settings.
The organism, known as Candida auris, is a type of yeast or fungus that can lead to severe and sometimes life-threatening infections. According to the Centers for Disease Control and Prevention, the fungus is especially troubling because it can survive on human skin and hard surfaces for months, even after routine cleaning and disinfection.
Unlike many other infections, Candida auris can spread easily through shared medical equipment and direct contact between people. Its ability to withstand commonly used disinfectants makes it difficult to eliminate once it enters a healthcare facility.
State health officials say cases have increased every year, pointing to a steady and worrying trend. “Each year, we have seen increases in our case counts which underscores the need for sustained vigilance,” the Alabama Department of Public Health told AL.com.
Nursing homes and long-term care facilities are bearing the brunt of the outbreak. According to ADPH, these settings face a higher risk because residents often have weakened immune systems and require frequent medical care.
“At this time, the Alabama Department of Public Health’s primary concern is the potential for unrecognized transmission within and between healthcare facilities,” the department said. Officials fear that infections may spread silently before being detected.
The health department confirmed via email that it is following the CDC’s recommended containment strategy to limit further spread. Healthcare providers and laboratories in Alabama are voluntarily reporting cases, although the state’s figures are not currently listed on the CDC’s national tracking dashboard, as per USA Today.
Alabama is not alone in dealing with the superbug. Nearby states are also seeing significant numbers. CDC data shows Tennessee has reported 189 cases, Mississippi 108, and Georgia 377. Florida, like Alabama, does not yet have figures publicly listed on the CDC website.
Candida auris was first identified in 2009 and has become increasingly common since then. The CDC said the fungus was first detected in the United States in 2016, when 51 cases were reported. By 2020, that number had climbed to more than 700.
This year, the rise has been sharp. As of December 20, 7,046 cases have been reported nationwide. In 2025 alone, 28 states recorded infections, with Nevada reporting the highest number of cases.
The fungus can infect different parts of the body, including the bloodstream, wounds, and ears. Symptoms vary depending on where the infection occurs and how severe it is. In some cases, people may not show symptoms at all.
The CDC noted that most patients who develop Candida auris infections are already seriously ill. This makes it difficult to determine how much the fungus contributes to death compared to other existing health conditions.
ADPH stressed that stopping the spread will require strong coordination across healthcare systems. “Continued collaboration with healthcare partners, timely reporting, and adherence to recommended infection control practices are critical to preventing further spread and limiting outbreaks,” the department said.
Health officials say ongoing awareness, strict hygiene measures, and early detection remain the best tools to contain this growing threat.
© 2024 Bennett, Coleman & Company Limited